ADAR1 Capital Management »

Travere Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Travere Therapeutics (TVTX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Travere Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Travere Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Travere Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $899 100 8.99

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Travere Therapeutics

Vanguard Group
Deutsche Bank Aktiengesellschaft
Kynam Capital Management
Jacobs Levy Equity Management
D. E. Shaw & Co
Bank of America Corporation
Goldman Sachs Group
Millennium Management
Emerald Advisers
Avidity Partners Management
Emerald Mutual Fund Advisers, Trust
Schonfeld Strategic Advisors
Barclays
Healthcare Of Ontario Pension Plan Trust Fund
Two Sigma Advisers

View all funds holding Travere Therapeutics